Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of primary amine oxidase activity. [GOC:TermGenie, PMID:23349812]
Negative regulation of primary amine oxidase activity involves a complex interplay of cellular mechanisms to control the activity of primary amine oxidases (PAOs). PAOs are a group of enzymes that catalyze the oxidative deamination of primary amines, producing aldehydes, ammonia, and hydrogen peroxide. These enzymes are crucial for a variety of physiological processes, including neurotransmission, inflammation, and detoxification. Dysregulation of PAO activity can contribute to various diseases, including Parkinson's disease, Alzheimer's disease, and cardiovascular diseases.
**Key mechanisms for negative regulation of PAO activity include:**
* **Gene expression regulation:** Transcriptional and post-transcriptional control of PAO gene expression can modulate enzyme levels. Factors such as hormones, cytokines, and environmental cues can influence the expression of PAO genes.
* **Protein synthesis and degradation:** The rate of PAO synthesis and its subsequent degradation play a significant role in controlling enzyme activity. Regulatory mechanisms can influence protein translation, folding, and stability, affecting PAO levels in the cell.
* **Post-translational modifications:** Various post-translational modifications, including phosphorylation, acetylation, and ubiquitination, can modulate PAO activity. These modifications can alter enzyme conformation, stability, and interactions with other molecules, ultimately influencing PAO activity.
* **Inhibitors and activators:** Specific inhibitors and activators can bind to PAO and modulate its activity. These molecules can act competitively or non-competitively, altering enzyme kinetics and influencing catalytic efficiency.
* **Cellular localization:** PAO activity can be regulated by its subcellular localization. Targeting of PAO to specific compartments within the cell can influence its interactions with substrates and regulators, controlling its overall activity.
* **Reactive oxygen species (ROS) regulation:** PAOs produce ROS as byproducts of their catalytic activity. In turn, ROS can also influence PAO activity, creating a feedback loop that modulates enzyme activity.
**Specific examples of negative regulators of PAO activity:**
* **MAOIs (Monoamine oxidase inhibitors):** These drugs are widely used to treat depression and anxiety. They work by inhibiting MAO, a type of PAO involved in neurotransmitter degradation.
* **Flavonoids:** These plant compounds have been shown to inhibit PAO activity in various studies, potentially contributing to their antioxidant and anti-inflammatory properties.
* **MicroRNAs:** These small non-coding RNAs can regulate PAO gene expression by targeting specific mRNA transcripts.
* **Other proteins:** Various proteins have been identified as potential regulators of PAO activity, interacting with the enzyme and influencing its function.
**Understanding the mechanisms of negative regulation of PAO activity is crucial for developing strategies to modulate PAO activity in various disease contexts. Targeting these regulatory pathways could offer new therapeutic approaches for treating disorders associated with PAO dysregulation.**'
"
Protein | Definition | Taxonomy |
---|---|---|
Membrane primary amine oxidase | A membrane primary amine oxidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16853] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
phenethylamine | 2-phenylethylamine : A phenylethylamine having the phenyl substituent at the 2-position. phenethylamine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7016 | alkaloid; aralkylamine; phenylethylamine | Escherichia coli metabolite; human metabolite; mouse metabolite |
phenelzine | Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC. | primary amine | |
benzimidazole | 1H-benzimidazole : The 1H-tautomer of benzimidazole. | benzimidazole; polycyclic heteroarene | |
benzylamine | aminotoluene : Any member of the class of toluenes carrying one or more amino groups. | aralkylamine; primary amine | allergen; EC 3.5.5.1 (nitrilase) inhibitor; plant metabolite |
2-aminobenzothiazole | benzothiazoles | ||
2-aminobenzimidazole | 2-aminobenzimidazole : A member of the class of benzimidazoles that is benzimidazole in which the hydrogen at position 2 is replaced by an amino group. 2-aminobenzimidazole: metabolite of benomyl; RN given refers to parent cpd | benzimidazoles | marine xenobiotic metabolite |
phenylguanidine | phenylguanidine: RN given refers to parent cpd | ||
3-phenylpropylamine | 3-phenylpropylamine : A phenylalkylamine that is benzene in which one of the hydrogens is substituted by a 3-aminopropyl group. | benzenes; phenylalkylamine; primary amino compound | |
maleic hydrazide | Maleic Hydrazide: 1,2-Dihydro-3,6-pyridazinedione. A herbicide and plant growth regulator; also used to control suckering of tobacco. Its residue in food and tobacco is highly toxic, causing CNS disturbances and liver damage. | pyridazinone | |
4-fluorobenzylamine | |||
2-amino-1-methylbenzimidazole | 2-amino-1-methylbenzimidazole: structure in first source | benzimidazoles | |
4-phenylbutylamine | 4-phenylbutylamine : A phenylalkylamine that is benzene in which one of the hydrogens is substituted by a 4-aminobutyl group. 4-phenylbutylamine: used as a drug partition into lipid bilayers in a cubic liquid-crystalline phase | benzenes; phenylalkylamine; primary amino compound | |
mofegiline |